---
id: anaerobic-cocci_076
category: organisms
tags: [anaerobic-cocci, Peptostreptococcus, Finegoldia-magna, Parvimonas-micra, metronidazole]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Anaerobic Cocci (Peptostreptococcus, Finegoldia, Parvimonas)

**Q:** What are the clinical syndromes and treatment of anaerobic cocci infections (Peptostreptococcus, Finegoldia magna, Parvimonas micra)?

**A:**

**Microbiology:**

**Gram-Positive Anaerobic Cocci (GPAC):**

**Major Genera:**
- **Peptostreptococcus anaerobius** (most common species in current taxonomy)
- **Finegoldia magna** (formerly Peptostreptococcus magnus)
- **Parvimonas micra** (formerly Peptostreptococcus micros / Micromonas micros)
- **Anaerococcus** species (formerly Peptostreptococcus)
- **Peptoniphilus** species (formerly Peptostreptococcus)

**Key Points:**
- **Part of normal flora:** Oral cavity, GI tract, female genital tract, skin
- **Taxonomic reclassification:** "Peptostreptococcus" is now multiple genera (Finegoldia, Parvimonas, Anaerococcus, Peptoniphilus)
- **Clinically:** Often still referred to collectively as "Peptostreptococcus" or "anaerobic cocci"

**Virulence Factors:**
- **Adhesins:** Bind to host tissues
- **Proteases:** Tissue destruction
- **Collagenase:** Tissue invasion

---

**Epidemiology:**

**Clinical Relevance:**
- **2nd most common anaerobic pathogens** (after Bacteroides fragilis)
- Found in **20-40% of anaerobic infections**
- **Almost always polymicrobial** (rarely sole pathogen)

**Risk Factors:**
- Disruption of mucosal barriers (trauma, surgery, dental procedures)
- Immunosuppression
- Diabetes
- Malignancy

---

**Clinical Syndromes:**

**1. Oral & Head/Neck Infections:**

**Dental Abscess:**
- **Polymicrobial:** Anaerobic cocci + Prevotella, Fusobacterium, viridans Streptococcus
- **Finegoldia magna, Parvimonas micra** common

**Periodontal Disease:**
- **Parvimonas micra** associated with periodontitis

**Brain Abscess (Odontogenic Source):**
- Contiguous spread from dental infection
- **Parvimonas micra, Finegoldia magna** common

**Lemierre Syndrome:**
- Polymicrobial (Fusobacterium necrophorum + anaerobic cocci)

**Ludwig Angina:**
- Bilateral submandibular space infection
- Polymicrobial including anaerobic cocci

---

**2. Pleuropulmonary Infections:**

**Aspiration Pneumonia:**
- **Oral flora anaerobes:** Peptostreptococcus, Prevotella, Fusobacterium
- Risk: Altered consciousness, dysphagia, poor dentition

**Lung Abscess:**
- Complication of aspiration pneumonia
- **Polymicrobial** (anaerobic cocci common)

**Empyema:**
- Often polymicrobial with anaerobic cocci

---

**3. Intra-Abdominal Infections:**

**Peritonitis / Intra-Abdominal Abscess:**
- **Polymicrobial:** Bacteroides fragilis + Enterobacterales + anaerobic cocci
- Anaerobic cocci found in **30-40%** of intra-abdominal infections

**Liver Abscess:**
- Polymicrobial (anaerobic cocci + Bacteroides, Streptococcus, Enterobacterales)

---

**4. Skin & Soft Tissue Infections:**

**Necrotizing Fasciitis (Type I - Polymicrobial):**
- **Anaerobic cocci + Bacteroides + Enterobacterales + Streptococcus**
- Fournier gangrene (perineal)

**Diabetic Foot Infection:**
- Polymicrobial (including anaerobic cocci if deep/necrotic)

**Cutaneous Abscess:**
- **Finegoldia magna** (most common GPAC in skin/soft tissue)

---

**5. Bone & Joint Infections:**

**Osteomyelitis:**
- **Chronic osteomyelitis** (especially skull, mandible, long bones)
- **Finegoldia magna, Peptostreptococcus anaerobius**
- Often polymicrobial

**Septic Arthritis:**
- Rare, but reported (especially prosthetic joint infections)
- **Finegoldia magna** most common

**Vertebral Osteomyelitis / Discitis:**
- Hematogenous spread
- **Finegoldia magna** associated

---

**6. Female Genital Tract Infections:**

**Tubo-Ovarian Abscess:**
- Polymicrobial: Anaerobic cocci + Bacteroides + Prevotella + E. coli

**Endometritis:**
- Postpartum, post-abortion
- Polymicrobial (including anaerobic cocci)

**Bacterial Vaginosis:**
- **Peptoniphilus** species (part of BV-associated flora)

---

**7. Bloodstream Infection:**

**Bacteremia:**
- **Finegoldia magna** most common GPAC in bacteremia
- Sources: Oral, GI, gynecologic, skin/soft tissue
- Often **polymicrobial** bacteremia

**Key Point:** **Finegoldia magna bacteremia** → Look for underlying abscess (brain, liver, bone)

---

**8. Prosthetic Device Infections:**

**Prosthetic Joint Infection:**
- **Finegoldia magna** increasingly recognized (chronic, indolent)
- Often **biofilm-associated**

**Cardiovascular Implantable Electronic Device (CIED) Infection:**
- Rare, but reported

---

**Species-Specific Associations:**

| **Species** | **Common Sites** | **Key Features** |
|-------------|------------------|------------------|
| **Finegolda magna** | Skin/soft tissue, bone/joint, bacteremia, brain abscess | **Most common GPAC in clinical infections**<br>Chronic, indolent infections<br>Biofilm producer |
| **Parvimonas micra** | Oral (periodontitis), brain abscess, head/neck | **Small cocci** (0.3-0.7 μm)<br>Odontogenic infections |
| **Peptostreptococcus anaerobius** | Intra-abdominal, pelvic, respiratory | GI/gynecologic flora |
| **Anaerococcus** spp. | Skin/soft tissue, urinary tract | Rare |
| **Peptoniphilus** spp. | Female genital tract (BV), skin/soft tissue | Part of vaginal flora |

---

**Diagnosis:**

**Culture:**
- **Anaerobic culture required** (will NOT grow on routine aerobic plates)
- **Slow growth:** 2-7 days (often missed if cultures stopped early)
- **Gram stain:** Gram-positive cocci in clusters or chains

**Blood Cultures:**
- Modern blood culture systems detect anaerobes (if held ≥5 days)

**Molecular Methods:**
- **16S rRNA sequencing** for speciation (Finegolda vs Parvimonas vs Peptostreptococcus)
- **MALDI-TOF** mass spectrometry (rapid identification)

**Key Point:** **Anaerobic cocci often missed** if cultures stopped early (<5 days)

---

**Treatment:**

**Key Principle:** **Anaerobic cocci are HIGHLY SUSCEPTIBLE** to most antibiotics (including β-lactams, metronidazole, clindamycin)

---

**1. First-Line Agents:**

**A. Penicillin-Based:**

| **Agent** | **Dosing** | **Efficacy** |
|-----------|------------|--------------|
| **Penicillin G** | 2-4 million units IV q4-6h | Excellent (>95% susceptible) |
| **Ampicillin** | 2g IV q6h | Excellent |
| **Amoxicillin** | 500-875 mg PO TID | Excellent (oral) |
| **Ampicillin-sulbactam** | 3g IV q6h | Excellent + broader coverage |
| **Piperacillin-tazobactam** | 3.375g IV q6h | Excellent + Pseudomonas |

**Key Point:** **Penicillin has EXCELLENT activity** against anaerobic cocci (unlike Bacteroides, which is penicillin-resistant)

**B. Metronidazole:**

**Dosing:**
- **Metronidazole** 500 mg IV/PO q8h

**Efficacy:**
- **Excellent activity** (>95% susceptible)
- Good CNS penetration (useful for brain abscess)

**C. Clindamycin:**

**Dosing:**
- **Clindamycin** 600-900 mg IV q8h OR 300-450 mg PO q6-8h

**Efficacy:**
- **Excellent activity** (>95% susceptible)
- Good bone penetration (osteomyelitis)

**Key Point:** **Clindamycin resistance rare** for anaerobic cocci (unlike Bacteroides fragilis with 15-30% resistance)

**D. Carbapenems:**

| **Agent** | **Dosing** | **Efficacy** |
|-----------|------------|--------------|
| **Ertapenem** | 1g IV q24h | Excellent |
| **Meropenem** | 1g IV q8h | Excellent |

**Efficacy:** **100% susceptible**

---

**2. Treatment by Syndrome:**

**Brain Abscess (Odontogenic Source):**

**Empiric Regimen:**
- **Ceftriaxone** 2g IV q12h + **Metronidazole** 500 mg IV q8h + **Vancomycin** 15-20 mg/kg IV q8-12h

**Rationale:**
- **Ceftriaxone:** Streptococcus (viridans)
- **Metronidazole:** Anaerobic cocci + Bacteroides, Prevotella, Fusobacterium
- **Vancomycin:** MRSA (if trauma/neurosurgery)

**Duration:** 4-8 weeks

---

**Aspiration Pneumonia / Lung Abscess:**

**Empiric Regimen:**
- **Ampicillin-sulbactam** 3g IV q6h (preferred)
- OR **Clindamycin** 600 mg IV q8h
- OR **Metronidazole** 500 mg IV q8h + **Ceftriaxone** 1-2g IV q24h

**Duration:**
- Pneumonia: 7-10 days
- Lung abscess: 3-4 weeks

---

**Necrotizing Fasciitis (Type I - Polymicrobial):**

**Empiric Regimen:**
- **Vancomycin** 15-20 mg/kg IV q8-12h + **Piperacillin-tazobactam** 3.375g IV q6h + **Clindamycin** 900 mg IV q8h

**Rationale:**
- **Vancomycin:** MRSA, Streptococcus pyogenes
- **Piperacillin-tazobactam:** Gram-negatives + anaerobes
- **Clindamycin:** Toxin suppression (exotoxins)

**Source Control:** **Urgent surgical debridement** (within 12h)

---

**Intra-Abdominal Infection:**

**Empiric Regimen:**
- **Ceftriaxone** 1-2g IV q24h + **Metronidazole** 500 mg IV q8h
- OR **Ertapenem** 1g IV q24h
- OR **Piperacillin-tazobactam** 3.375g IV q6h

**Duration:** 4-7 days (after source control)

---

**Prosthetic Joint Infection (Finegolda magna):**

**Treatment:**
- **Penicillin G** 2-4 million units IV q4-6h OR **Ampicillin** 2g IV q6h
- OR **Clindamycin** 600 mg IV q8h (if penicillin allergy)

**Duration:**
- **4-6 weeks IV** (if device retained with debridement)
- Followed by **oral suppression** 3-6 months (if device retained)
- **Shorter course (2-4 weeks)** if 2-stage exchange (device removed)

**Surgical Management:**
- **DAIR** (debridement, antibiotics, implant retention) if early (<3 weeks) OR **2-stage exchange** if chronic

**Key Point:** **Finegoldia magna biofilm producer** → Device removal often needed

---

**Osteomyelitis (Chronic):**

**Treatment:**
- **Penicillin G** 2-4 million units IV q4-6h OR **Ampicillin** 2g IV q6h
- OR **Clindamycin** 600 mg IV q8h (good bone penetration)

**Duration:** **6 weeks IV** (at least 4 weeks)

---

**Resistance Patterns:**

**Susceptibility (Anaerobic Cocci):**
- **Penicillin:** >95% susceptible
- **Metronidazole:** >95% susceptible
- **Clindamycin:** >95% susceptible
- **Carbapenems:** 100% susceptible
- **Vancomycin:** 100% susceptible

**Key Point:** **Anaerobic cocci have LOW resistance rates** (unlike Bacteroides fragilis with β-lactamase)

**Resistance Mechanisms (Rare):**
- β-lactamase production (very rare)
- Clindamycin resistance (rare, <5%)

---

**Biofilm Formation:**

**Finegolda magna:**
- **Strong biofilm producer** (prosthetic device infections)
- Biofilm → ↓ antibiotic penetration → Device removal often necessary

---

**Mnemonic: "FAME for Anaerobic Cocci"**
- **F**inegolda magna = most common GPAC
- **A**naerobic cocci = 2nd most common anaerobes (after Bacteroides)
- **M**etronidazole / Penicillin / Clindamycin all work (>95% susceptible)
- **E**xcellent susceptibility (unlike B. fragilis resistance)

**Mnemonic: "Peptostreptococcus = Polymicrobial"**
- **P**olymicrobial infections (rarely sole pathogen)
- **P**enicillin-susceptible (unlike Bacteroides)
- **P**rosthetic joint infections (Finegolda magna)

**Clinical Pearls:**
- **Finegolda magna = #1 GPAC in clinical infections** (skin/soft tissue, bone/joint, bacteremia, brain abscess)
- **Parvimonas micra = odontogenic infections** (periodontitis, brain abscess)
- **Anaerobic cocci = 2nd most common anaerobes** (after Bacteroides fragilis)
- **Almost always polymicrobial** (rarely sole pathogen)
- **>95% susceptible to penicillin, metronidazole, clindamycin** (unlike Bacteroides)
- **Slow growth (2-7 days)** → Cultures may be falsely negative if stopped early
- **Finegolda magna = biofilm producer** → Prosthetic device removal often needed
- **Clindamycin resistance rare for anaerobic cocci** (<5%, unlike 15-30% for B. fragilis)
- **Penicillin works for anaerobic cocci** (does NOT work for Bacteroides)
- **Finegoldia magna bacteremia** → Look for underlying abscess (brain, liver, bone)

**Media:** None

**Sources:** [Mandell's Principles 9th edition - Anaerobic cocci], [PMC 2024 - Finegolda magna pathogenesis], [Clinical Microbiology Reviews 2023 - Gram-positive anaerobic cocci], [Anaerobe Journal 2024 - GPAC clinical significance], [IDSA 2017 - Brain abscess treatment], [PMC 2022 - Finegolda magna prosthetic joint infection]
